Thursday, August 27, 2026
← Back to archivePolicy
Policy•STAT News•Aug 27, 2026
Hospitals are plotting a long-shot push to roll back $1 trillion in Medicaid cuts
background ▾
- •Hospital systems are organizing a coordinated lobbying effort to challenge $1 trillion in legislatively-mandated Medicaid cuts, with both near-term mitigation strategies and a multi-year political realignment plan
- •Democrats including Senate Minority Leader Schumer and top Finance Committee members have signaled willingness to roll back cuts if they regain power, while some Republicans (Hawley, Murkowski, Collins, Moran) have expressed concerns despite voting for the original legislation
- •Monitor 2024-2025 election outcomes and subsequent legislative negotiations, as success will require either substantial Republican defections from a signature tax achievement or Democratic control of both chambers plus the presidency by 2028
Policy•STAT News•Aug 27, 2026
Opinion: STAT+: A bill is supposed to protect U.S. biotech from Chinese competition. But there’s a loophole
background ▾
- •BINSA proposes significantly broadened federal oversight of biotechnology R&D and manufacturing as a companion measure to the COINS Act, directly responding to major pharma partnerships with Chinese biotech companies
- •Despite bipartisan framing around national security, the legislation reportedly contains a significant loophole that may undermine its stated protective purpose for U.S. biotech interests
- •Monitor congressional deliberations and final bill language to clarify the loophole and assess actual regulatory impact on U.S.-China pharma collaborations and global drug development strategies
PfizerBristol Myers Squibb
→ Read original articlePolicy•STAT News•Aug 27, 2026
A state gave sheriffs 20% of its opioid settlement cash. We followed the money
background ▾
- •Louisiana's 20% sheriff allocation represents the largest law enforcement carve-out of opioid settlement funds in the U.S., with sheriffs having broad discretion and minimal reporting requirements despite receiving billions.
- •Recovery advocates and public health experts argue the spending—including drones and vehicles—contradicts the spirit of settlements and diverts finite resources from evidence-based addiction treatment and prevention programs.
- •As Purdue Pharma's $7.4 billion bankruptcy finalizes and settlement payouts continue for a decade-plus, the lack of national guardrails on fund allocation will likely fuel ongoing disputes over whether money supports law enforcement or treatment/harm reduction.
Purdue PharmaOxyContin
→ Read original articlePolicy•KFF•Aug 26, 2026
Medicaid Coverage for Women
background ▾
- •Women are overrepresented in Medicaid, comprising the majority of the adult population, with women of reproductive age alone representing one-quarter of total Medicaid enrollment
Policy•KFF•Aug 26, 2026
Availability of Rural Hospitals Providing Inpatient Maternity Care in Medicaid
background ▾
- •Nearly half of rural hospitals have already eliminated obstetrics units; the 2025 reconciliation law's Medicaid cuts threaten to accelerate further closures, particularly among remote rural hospitals already facing 43-minute average drive times to alternative providers
- •Medicaid finances nearly half of all births in rural communities and covers 1 in 4 rural women of reproductive age, making reimbursement policy directly determinative of rural maternity care access and maternal/neonatal health outcomes
- •Monitor rural hospital obstetric service closures and Medicaid enrollment changes post-reconciliation; track state-level responses to the $50 billion rural health fund allocation and whether supplemental obstetric payment initiatives can sustain rural maternity infrastructure
Market Access
Market Access•Fierce Biotech•Aug 26, 2026
Medigen links up with Charles River in push to take enterovirus vaccine global
background ▾
- •Medigen's Envacgen EV71 vaccine has regional approval (Taiwan, Vietnam) and is now being positioned for global development through a CRO partnership focused on regulatory-compliant manufacturing and analytics
- •Charles River's NGS and biologics testing expertise is being leveraged to de-risk the chemistry, manufacturing, and controls pathway ahead of international regulatory submissions
Charles River LaboratoriesMedigen Vaccine BiologicsEnvacgen
→ Read original articleMarket Access•Fierce Biotech•Aug 26, 2026
JATT mastermind launches latest biotech-focused SPAC via $60M IPO
background ▾
- •Sidhu's third SPAC launch reflects persistent use of the SPAC model despite declining market enthusiasm, though recent traditional IPO successes suggest the model's competitive disadvantage
JATT III AcquisitionZura BioTalawar Therapeutics
→ Read original articleMarket Access•Fierce Biotech•Aug 26, 2026
Hansoh heralds China’s move from ‘follower’ to ‘frontrunner’ in biopharma race
background ▾
- •Chinese biotech assets now comprise 30% of global investigational medicines and are projected to represent >66% of licensing deal value in 2024, up from 50% in 2023 and 5% five years ago—a dramatic acceleration in China's share of global dealmaking
- •Hansoh's expansion to 40+ pipeline candidates in 70+ clinical trials, combined with 20.7% R&D spending growth, demonstrates sustained capital deployment despite geopolitical tensions and U.S. policy scrutiny
- •Watch for U.S. policy actions restricting American pharma access to Chinese biotech assets; dealmaking momentum and Chinese CEO confidence suggest near-term resilience, but regulatory barriers could reshape partnership patterns
Hansoh PharmaceuticalGSKMerck & Co.
→ Read original articleMarket Access•Endpoints News•Aug 26, 2026
Cellares rebukes Bristol Myers' criticism of its cell therapy technology
background ▾
- •Bristol Myers Squibb terminated a manufacturing agreement with Cellares, questioning the commercial readiness of Cellares' cell therapy manufacturing technology
- •This contract failure highlights manufacturing scalability challenges in the cell therapy sector and potential risks for startups dependent on partnerships with major pharma
- •Monitor whether other cell therapy programs supported by Cellares' platform face similar manufacturing concerns or whether Cellares secures alternative partnerships
CellaresBristol Myers Squibb
→ Read original articleMarket Access•Endpoints News•Aug 26, 2026
Biohaven strikes $795M deal for commercial partner in epilepsy
background ▾
- •Biohaven monetizes commercialization risk through a $795M partnership, securing non-dilutive capital and eliminating the need for independent global infrastructure build-out
- •SK Biopharmaceuticals gains access to a late-stage epilepsy asset with potential to strengthen its neurology franchise, particularly in high-value markets
- •Success depends on regulatory approval and clinical differentiation—market access and reimbursement outcomes in major markets remain uncertain
BiohavenSK Biopharmaceuticals
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Aug 26, 2026
Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate
background ▾
- •Ivonescimab demonstrated clinically meaningful and statistically significant OS benefit over Imfinzi-chemo in biliary tract cancer, marking the first phase 3 win outside NSCLC and validating the PD-1xVEGF bispecific construct across multiple indications.
- •Harmoni-GI1 enrolled ~700 patients in just 11 months, reflecting significant unmet need; biliary tract cancer has 100,000+ new cases annually in China alone, though global market is valued at $1-4 billion—much smaller than NSCLC opportunity.
- •A registrational phase 2/3 trial in biliary tract cancer is slated to begin early 2025 with a global population, potentially enabling regulatory pathways outside China; however, investor and analyst focus remains concentrated on the imminent Harmoni-3 NSCLC readout.
AkesoSummit TherapeuticsAstraZenecaivonescimabImfinziTecentriq
→ Read original articleClinical Trials•Fierce Biotech•Aug 26, 2026
FDA greenlights Revolution Medicines' pancreatic cancer gamechanger
background ▾
- •Daraxonrasib achieved unprecedented efficacy in pancreatic cancer by doubling both overall survival and progression-free survival through a novel mechanism that glues RAS to cyclophilin A, addressing a historically undruggable oncology target
- •The expedited FDA approval via Commissioner's Priority Voucher and six-month ahead-of-deadline review reflects the agency's assessment of critical unmet need and breakthrough clinical data
- •Revolution Medicines' pipeline strategy includes advancing daraxonrasib into earlier treatment lines, advancing zoldonrasib into Phase 3, and developing additional RAS inhibitors—watch for competitive pressure as other pharma companies race to enter the RAS-targeting space
Revolution MedicinesdaraxonrasibRasonquezoldonrasib
→ Read original articleClinical Trials•STAT News•Aug 27, 2026
Opinion: I studied Reddit forums on menopause — and found what doctors are missing
background ▾
- •Clinical records substantially underrepresent cognitive symptoms (brain fog, memory problems) and emotional symptoms that patients actively discuss in online forums, indicating a documentation gap that cascades into incomplete research and guidelines
- •Women report systematic dismissal of menopause-related cognitive and mood symptoms by clinicians, leading to misdiagnosis as psychiatric or neurological conditions and potentially reducing symptom reporting in future clinical encounters
- •Future menopause research and clinical trial design should incorporate cognitive and emotional symptom assessment based on patient-reported experiences from non-clinical settings to ensure comprehensive characterization of menopause burden
Clinical Trials•Endpoints News•Aug 26, 2026
An uncertain future for Aurora, the first startup dedicated to custom CRISPR therapies
background ▾
- •Aurora Therapeutics, the first company dedicated solely to custom/personalized CRISPR therapies, has halted its lead program and reduced staff
- •The company's struggle suggests that the bespoke gene editing model may face significant scalability, manufacturing, or clinical challenges that threaten its differentiated business strategy
- •Watch for Aurora's strategic pivot, potential partnerships, or further restructuring; outcome may inform investor confidence in personalized versus platform CRISPR approaches
Aurora Therapeutics
→ Read original articleClinical Trials•STAT News•Aug 26, 2026
On the fence about a statin? In borderline cases, calcium scans could be a tiebreaker
background ▾
- •CAC scans improve cardiovascular risk stratification specifically for borderline-risk patients (PREVENT 3-5%) but provide minimal benefit (1-2% improvement) when applied universally, making them useful as a tiebreaker rather than routine screening
- •Incidental CAC findings from CT scans performed for other clinical indications predict cardiovascular events as effectively as dedicated CAC scans, potentially reducing unnecessary out-of-pocket costs ($100-$400)
- •These findings are reshaping statin initiation discussions in primary prevention; clinicians should incorporate CAC selectively in borderline cases while recognizing that CAC-zero scores should not preclude statin therapy in appropriately risk-stratified patients
statins
→ Read original article